SS-31, MOTS-c, and Tesamorelin: Evidence

People using retatrutide for weight loss are increasingly asking about adding longevity-oriented peptides such as SS-31, MOTS-c, GHK-Cu, and tesamorelin to their regimens. The question usually comes down to the same thing: what does the research actually support, and where does the evidence run out? This article covers what is known about each compound, noted honestly by evidence quality.

A brief note before the science: none of this constitutes medical advice. People combining investigational peptides with an approved or unapproved drug do so outside any clinical framework, and the interactions between these compounds have not been studied in humans. Consult a clinician before using any of these compounds.

SS-31 (elamipretide): mitochondria as the target

SS-31, also called elamipretide, is a tetrapeptide that binds cardiolipin, a lipid in the inner mitochondrial membrane. By stabilising the cristae structure there, SS-31 appears to reduce oxidative stress and support ATP production^[1]. The mechanism is specific enough that the compound has been tested in several Phase 2 and Phase 3 trials, including PROGRESS-HF (heart failure), TAZPOWER (Barth syndrome), and MMPOWER-3 (primary mitochondrial myopathy). Those trials enrolled patients with established mitochondrial or cardiac disease, not healthy people optimising wellness.

The evidence quality for SS-31 as a longevity or performance tool in otherwise healthy adults is thin. Animal and preclinical data are extensive; the human trials focus on pathological mitochondrial dysfunction. Whether the same ATP-stabilising effect is meaningful in people with normal mitochondrial function is not yet established. The 2025 review covering the compound's clinical pipeline notes the need for further work on long-term efficacy and safety before its use is expanded beyond disease contexts.

MOTS-c: the exercise-mimetic peptide

MOTS-c is a peptide encoded by mitochondrial DNA, not nuclear DNA. It is released from skeletal muscle during exercise and circulates as a systemic signal. In animal models, MOTS-c targets skeletal muscle and adipose tissue to improve glucose metabolism, boost exercise performance, and stimulate thermogenesis in white fat^[2]. The 2022 PMID 35656563 review describes how exercise triggers reactive oxygen species production that prompts MOTS-c release, and how exogenous MOTS-c administration replicates some of those adaptive responses.

There are no published randomised controlled trials of MOTS-c in humans. All data showing metabolic and exercise effects come from rodent studies or review articles synthesising those findings. That makes MOTS-c genuinely interesting from a mechanistic standpoint, but the evidence quality for any human application remains preclinical. The distance between mouse exercise physiology and human exercise physiology is large enough that the animal results should not be read as proof of effect in people.

GHK-Cu: tissue repair and skin biology

GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine. It occurs naturally in human blood and declines with age, from roughly 200 ng/mL at age 20 to around 80 ng/mL by age 60^[3]. In laboratory and animal studies it stimulates collagen and glycosaminoglycan synthesis, promotes wound closure, and shows anti-inflammatory properties. Animal data cover wound healing in skin, hair follicles, gastrointestinal tissue, and bone. Cosmetic preparations using GHK-Cu have been used topically for decades.

The catch is that most of the evidence base is preclinical. Published reviews note the rationale for further human investigation but acknowledge that rigorous clinical trial data in humans is currently absent. The claim sometimes seen in wellness circles that GHK-Cu upregulates thousands of human genes derives from in vitro gene-expression data, not clinical outcomes. Anyone citing those numbers should read the original cell-culture context before drawing conclusions about whole-body effects.

Tesamorelin: the one with an FDA approval

Tesamorelin occupies a different category from the three peptides above. It is a synthetic analogue of growth hormone-releasing factor (GRF) and is FDA-approved under the brand name EGRIFTA SV for the reduction of excess visceral abdominal fat in HIV-infected adults with lipodystrophy^[4]. The prescribing information is specific: tesamorelin binds GRF receptors in the pituitary gland and stimulates endogenous growth hormone release. The label explicitly states the drug is not indicated for general weight loss management.

The interest in tesamorelin outside its approved indication relates to its growth hormone-stimulating effect and the potential for visceral fat reduction in people who are not HIV-positive. The available data on this use is limited to small studies and case series, not the kind of controlled trial that supports the FDA label. Key safety signals from the prescribing information include elevated IGF-1 levels requiring monitoring, fluid retention and associated joint pain, increased risk of glucose intolerance or new diabetes, and contraindication in patients with a history of malignancy because of the neoplasm-risk warning.

A note on FoxDri04

The signal post that prompted this article mentioned a peptide called FoxDri04 alongside the others. A search of PubMed returns no results for this name. It may be a misspelling, a vendor trade name with no published literature, or a compound too recent for indexed research. Because there are no peer-reviewed papers to cite, FoxDri04 is not covered here. Readers asking about this compound should verify whether any published safety or efficacy data exists before considering use.

What we do not yet know

The clearest gap across all four peptides is human pharmacokinetic and interaction data. None of the clinical work on SS-31, MOTS-c, or GHK-Cu was designed to assess co-administration with a GLP-1 or GIP class drug. Retatrutide itself is still in Phase 3 trials and is not approved by the FDA, the EMA, or the MHRA. Combining a triple-agonist investigational drug with preclinical-only peptides produces a stack with no published safety or interaction data at all. That does not mean harm is certain, but it does mean the risk profile is genuinely unknown.

For tesamorelin, the interaction picture is somewhat better defined because the compound has an approved label, but the label applies to a specific patient population under clinical supervision. Off-label use, particularly in people who are not HIV-positive and not under specialist care, sits outside the evidence base the FDA reviewed.